27.93

0.83% 0.23

Pre-market: 28.35 0.42 +1.50%

Roivant Sciences Ltd (ROIV)

Overview News Price History Option Chain Financials Why ROIV Down? Discussions Forecast

Roivant Sciences Ltd stock is traded at $27.93, with a volume of 4.91M. It is up +0.83% in the last 24 hours and up +0.61% over the past month. Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Previous Close:

$27.70

Open:

$28.03

24h Volume:

4.91M

Relative Volume:

0.72

Market Cap:

$19.99B

Revenue:

$13.31M

Net Income/Loss:

$-1.01B

P/E Ratio:

-23.90

EPS:

-1.1685

Net Cash Flow:

$-766.86M

1W Performance:

-1.24%

1M Performance:

+0.61%

6M Performance:

+89.48%

1Y Performance:

+158.85%

1-Day Range:

$27.66

$28.39

1-Week Range:

$27.12

$28.46

52-Week Range:

$8.73

$30.33

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name

Roivant Sciences Ltd

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

441-295-5950

Address

7TH FLOOR, 50 BROADWAY, LONDON

Employee

750

Twitter

Next Earnings Date

2025-02-10

Latest SEC Filings

ROIV's Discussions on Twitter

Compare ROIV vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ROIV Roivant Sciences Ltd	27.93	19.99B	13.31M	-1.01B	-766.86M	-1.1685
VRTX Vertex Pharmaceuticals Inc	451.24	114.63B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	736.53	77.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	681.85	42.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	306.66	40.67B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	143.98	31.04B	606.42M	-1.28B	-997.58M	-6.403

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-20-26	Initiated	Bernstein	Outperform
Sep-02-25	Initiated	Citigroup	Buy
Jul-10-25	Resumed	Goldman	Buy
Feb-15-24	Initiated	Wolfe Research	Outperform
Jan-05-24	Initiated	Piper Sandler	Overweight
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-17-23	Initiated	Guggenheim	Buy
Jun-08-23	Initiated	BofA Securities	Neutral
Oct-27-22	Initiated	JP Morgan	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight
Dec-15-21	Initiated	Goldman	Buy
Nov-08-21	Initiated	H.C. Wainwright	Buy
Oct-28-21	Initiated	Citigroup	Buy
Oct-26-21	Initiated	Cowen	Outperform
Oct-26-21	Initiated	Jefferies	Buy
Oct-26-21	Initiated	Truist	Buy

View All

Roivant Sciences Ltd Stock (ROIV) Latest News

03:31 AM

Assenagon Asset Management S.A. Purchases 6,877,348 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat

03:31 AM

Mar 23, 2026

Roivant Sciences, Genevant, Arbutus, and Moderna Settle International Patent Litigation – Key Terms and Confidentiality Details - Minichart

Mar 23, 2026

Mar 22, 2026

Roivant Sciences (ROIV) soars 19.4% as pipeline drugs progress - MSN

Mar 22, 2026

Roivant secures FDA priority review for dermatomyositis treatment - MSN

Mar 22, 2026

Mar 21, 2026

Risk Analysis: Is Roivant Sciences Ltd backed by strong institutional buyingBreakout Watch & High Conviction Investment Ideas - baoquankhu1.vn

Mar 21, 2026

Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Mar 21, 2026

(ROIV) Risk Channels and Responsive Allocation - Stock Traders Daily

Mar 21, 2026

Mar 20, 2026

Bernstein initiates Roivant Sciences stock with outperform rating - Investing.com

Mar 20, 2026

Sanford C. Bernstein Begins Coverage on Roivant Sciences (NASDAQ:ROIV) - MarketBeat

Mar 20, 2026

Roivant Sciences Insider Sold Shares Worth $5,648,000, According to a Recent SEC Filing - marketscreener.com

Mar 20, 2026

Mar 19, 2026

Roivant Sciences (NASDAQ:ROIV) CEO Sells 200,000 Shares - MarketBeat

Mar 19, 2026

Roivant (NASDAQ: ROIV) president exercises 200K options and sells 200K shares - Stock Titan

Mar 19, 2026

Trade Recap: What is the dividend yield of Roivant Sciences LtdShort Setup & AI Based Trade Execution Alerts - baoquankhu1.vn

Mar 19, 2026

Roivant Sciences Insider Sold Shares Worth $1,200,573, According to a Recent SEC Filing - marketscreener.com

Mar 19, 2026

Mar 18, 2026

Insider Sell Alert: Melissa Epperly Sells 41,861 Shares of Roiva - GuruFocus

Mar 18, 2026

Roivant Sciences (NASDAQ:ROIV) Director Melissa Epperly Sells 41,861 Shares - MarketBeat

Mar 18, 2026

Roivant Sciences (ROIV) director sells 41,861 common shares - Stock Titan

Mar 18, 2026

Aug Catalysts: Can Roivant Sciences Ltd outperform under higher oil prices2026 PreEarnings & Growth Oriented Trade Recommendations - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

Rockefeller Financial to sell 200,000 Roivant shares (ROIV) - Stock Titan

Mar 17, 2026

Aug Reactions: Is Roivant Sciences Ltd stock undervalued right nowWeekly Stock Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn

Mar 17, 2026

Bamco Inc. NY Acquires 105,000 Shares in Roivant Sciences Ltd. - National Today

Mar 17, 2026

105,000 Shares in Roivant Sciences Ltd. $ROIV Acquired by Bamco Inc. NY - MarketBeat

Mar 17, 2026

Mar 16, 2026

Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? - MSN

Mar 16, 2026